The NCMAG Council makes decisions on the proposed use of cancer medicines. Our advice documents give details of our decisions and the reason(s) for supporting or not supporting the use of a medicine.
Medicine review process
These advice documents present the details and an analysis of the quality of the clinical and the economic evidence for the medicine reviewed. Council members use this evidence to make a decision.
Once a decision has been made on the use of a medicine, the document informs NHS Boards and their Area Drug and Therapeutic Committees (ADTC). They can then determine medicines for local use or local formulary inclusion.
Published advice
| Publication date | Medicine | Use | Decision | Advice document |
|---|---|---|---|---|
| Publication date 18 January 2024 | Medicine Sunitinib | Use Second line treatment of adult patients with poor or intermediate risk advanced/metastatic renal cell carcinoma who have received nivolumab in combination with ipilimumab as first line treatment. (Off-patent use) | Decision Supported | Advice document |
| Publication date 18 January 2024 | Medicine Pazopanib | Use Second line treatment of adult patients with poor or intermediate risk advanced/metastatic renal cell carcinoma who have received nivolumab in combination with ipilimumab as first line treatment. (Off-label use) | Decision Not supported | Advice document |
| Publication date 26 October 2023 | Medicine Nivolumab | Use Treatment of patients with pleural or peritoneal mesothelioma; second or subsequent line. (Off-label use) | Decision Supported | Advice document |
| Publication date 26 October 2023 | Medicine Dabrafenib plus trametinib | Use Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options (Off-label use) | Decision Supported | Advice document |
| Publication date 27 July 2023 | Medicine Pemetrexed plus cisplatin | Use Adjuvant treatment for patients with completely resected stage II to IIIA nonsquamous non–small-cell lung cancer (Off-label use) | Decision Supported | Advice document |
| Publication date 27 July 2023 | Medicine Abiraterone | Use Treatment for newly diagnosed low-risk hormone sensitive metastatic prostate cancer patients who are not suitable for currently available on-label alternatives. (Off-label use) | Decision Supported | Advice document |
| Publication date 27 April 2023 | Medicine Vinorelbine | Use Treatment of pleural mesothelioma; second or subsequent line in patients whose disease has progressed on or after prior treatment with platinum based chemotherapy and/or immunotherapy. (Off-label use) | Decision Not supported | Advice document |
| Publication date 12 January 2023 | Medicine Abiraterone plus prednisolone in addition to androgen deprivation therapy | Use Adults with high-risk hormone-sensitive non-metastatic prostate cancer. (Off-label use)Enter content | Decision Supported | Advice document NCMAG102 (re-evaluation, supersedes NCMAG101) |
| Publication date 12 January 2023 | Medicine Carfilzomib plus dexamethasone | Use Once weekly dosing of carfilzomib for adult patients with multiple myeloma who have received at least one prior therapy. (Off-label use) | Decision Supported | Advice document |
| Publication date 12 January 2023 | Medicine Trastuzumab | Use The treatment duration of 6-months, or 9 cycles, for adult patients categorised as lower risk with human epidermal growth factor receptor 2 (HER2) positive early breast cancer (EBC) in the neo-adjuvant and adjuvant treatment pathways. (Off-label use) | Decision Supported | Advice document |
| Publication date 20 October 2022 | Medicine Lenalidomide plus dexamethasone | Use Adults with previously untreated multiple myeloma who are not eligible for transplant, and are suitable for thalidomide-containing regimen. (On-label use and off-patent medicines) | Decision Supported | Advice document |